{"transactions":[{"id":4630562,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-10-05T20:59:26.000Z","date":"2026-10-02","kind":"exercise","planned":false,"acquired":false,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vested on September 8, 2022, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":57405,"derivative":{"exercise_price":2.32,"expiration_date":"2031-09-08","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0002009130-26-000006","document":"wk-form4_1791233964.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000200913026000006/wk-form4_1791233964.xml","form_type":"4"}},{"id":4630561,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Common Stock","published_at":"2026-10-05T20:59:26.000Z","date":"2026-10-02","kind":"exercise","planned":false,"acquired":true,"shares":55000,"price":2.32,"value":127600.0,"ownership":{"direct":true},"balance_after":79060,"source":{"system":"sec-edgar","filing":"0002009130-26-000006","document":"wk-form4_1791233964.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000200913026000006/wk-form4_1791233964.xml","form_type":"4"}},{"id":4634293,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-10-02T05:33:36.000Z","date":"2026-09-30","kind":"exercise","planned":false,"acquired":false,"shares":24056,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":121818,"derivative":{"exercise_price":2.35,"expiration_date":"2033-12-19","underlying":"Common Stock","underlying_shares":24056},"source":{"system":"sec-edgar","filing":"0002009130-26-000004","document":"wk-form4_1790904813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000200913026000004/wk-form4_1790904813.xml","form_type":"4"}},{"id":4634292,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-10-02T05:33:36.000Z","date":"2026-09-29","kind":"exercise","planned":false,"acquired":false,"shares":54375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":35625,"derivative":{"exercise_price":2.35,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":54375},"source":{"system":"sec-edgar","filing":"0002009130-26-000004","document":"wk-form4_1790904813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000200913026000004/wk-form4_1790904813.xml","form_type":"4"}},{"id":4634291,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-10-02T05:33:36.000Z","date":"2026-09-29","kind":"exercise","planned":false,"acquired":false,"shares":56455,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":145874,"derivative":{"exercise_price":2.35,"expiration_date":"2033-12-19","underlying":"Common Stock","underlying_shares":56455},"source":{"system":"sec-edgar","filing":"0002009130-26-000004","document":"wk-form4_1790904813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000200913026000004/wk-form4_1790904813.xml","form_type":"4"}},{"id":4634290,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Common Stock","published_at":"2026-10-02T05:33:36.000Z","date":"2026-09-30","kind":"sale","planned":false,"acquired":false,"shares":886,"price":26.87,"value":23806.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."}],"balance_after":24060,"source":{"system":"sec-edgar","filing":"0002009130-26-000004","document":"wk-form4_1790904813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000200913026000004/wk-form4_1790904813.xml","form_type":"4"}},{"id":4634289,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Common Stock","published_at":"2026-10-02T05:33:36.000Z","date":"2026-09-30","kind":"sale","planned":false,"acquired":false,"shares":23170,"price":25.7786,"value":597290.162,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."}],"balance_after":24946,"source":{"system":"sec-edgar","filing":"0002009130-26-000004","document":"wk-form4_1790904813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000200913026000004/wk-form4_1790904813.xml","form_type":"4"}},{"id":4634288,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Common Stock","published_at":"2026-10-02T05:33:36.000Z","date":"2026-09-30","kind":"exercise","planned":false,"acquired":true,"shares":24056,"price":2.35,"value":56531.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."}],"balance_after":48116,"source":{"system":"sec-edgar","filing":"0002009130-26-000004","document":"wk-form4_1790904813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000200913026000004/wk-form4_1790904813.xml","form_type":"4"}},{"id":4634287,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Common Stock","published_at":"2026-10-02T05:33:36.000Z","date":"2026-09-29","kind":"sale","planned":false,"acquired":false,"shares":110830,"price":26.5826,"value":2946149.558,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This price is a weighted average price. These securities were sold in multiple transactions at prices ranging from $26.5513 to $26.5902 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":24060,"source":{"system":"sec-edgar","filing":"0002009130-26-000004","document":"wk-form4_1790904813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000200913026000004/wk-form4_1790904813.xml","form_type":"4"}},{"id":4634286,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Common Stock","published_at":"2026-10-02T05:33:36.000Z","date":"2026-09-29","kind":"exercise","planned":false,"acquired":true,"shares":54375,"price":2.35,"value":127781.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."}],"balance_after":134890,"source":{"system":"sec-edgar","filing":"0002009130-26-000004","document":"wk-form4_1790904813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000200913026000004/wk-form4_1790904813.xml","form_type":"4"}},{"id":4634285,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Common Stock","published_at":"2026-10-02T05:33:36.000Z","date":"2026-09-29","kind":"exercise","planned":false,"acquired":true,"shares":56455,"price":2.35,"value":132669.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."}],"balance_after":80515,"source":{"system":"sec-edgar","filing":"0002009130-26-000004","document":"wk-form4_1790904813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000200913026000004/wk-form4_1790904813.xml","form_type":"4"}},{"id":758947,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-29T20:16:01.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the Reporting Person did not pay any consideration for the derivative securities."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest in 36 equal monthly installments commencing on June 27, 2026, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":26000,"derivative":{"exercise_price":20.44,"expiration_date":"2036-05-26","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001777760-26-000016","document":"wk-form4_1780085758.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000177776026000016/wk-form4_1780085758.xml","form_type":"4"}},{"id":777306,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":46948,"kind":"person","name":"Etkin Amit","position":1,"cik":"0002007795","reported_name":"Etkin Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-05-15T21:06:10.000Z","date":"2026-05-14","kind":"gift","planned":false,"acquired":false,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person transferred 400,000 shares for estate planning purposes to the Bard on Haven Trust, an irrevocable trust, for the benefit of his spouse and children as a bona fide gift for no consideration. The trustee of the trust is independent of the reporting person, and the reporting person does not have voting, dispositive, or pecuniary interest over any of the securities held by the trust."}],"balance_after":833949,"source":{"system":"sec-edgar","filing":"0002007795-26-000006","document":"wk-form4_1778879168.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000200779526000006/wk-form4_1778879168.xml","form_type":"4"}},{"id":779465,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":39725,"kind":"person","name":"Sanchez Ramiro","position":1,"cik":"0001830326","reported_name":"Sanchez Ramiro","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T21:00:21.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":10958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":10958,"derivative":{"exercise_price":24.63,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":10958},"source":{"system":"sec-edgar","filing":"0001830326-26-000005","document":"wk-form4_1778792418.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000183032626000005/wk-form4_1778792418.xml","form_type":"4"}},{"id":779467,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":45308,"kind":"person","name":"Cox Christopher Nixon","position":1,"cik":"0002008212","reported_name":"Cox Christopher Nixon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T20:58:43.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":10958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":10958,"derivative":{"exercise_price":24.63,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":10958},"source":{"system":"sec-edgar","filing":"0002008212-26-000004","document":"wk-form4_1778792320.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008212/000200821226000004/wk-form4_1778792320.xml","form_type":"4"}},{"id":779472,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":47392,"kind":"person","name":"Manji Husseini","position":1,"cik":"0002009654","reported_name":"Manji Husseini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T20:57:34.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":10958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":10958,"derivative":{"exercise_price":24.63,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":10958},"source":{"system":"sec-edgar","filing":"0002009654-26-000004","document":"wk-form4_1778792252.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009654/000200965426000004/wk-form4_1778792252.xml","form_type":"4"}},{"id":779464,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":47389,"kind":"person","name":"Dreyfus Andrew","position":1,"cik":"0001670893","reported_name":"Dreyfus Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T20:56:57.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":10958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":10958,"derivative":{"exercise_price":24.63,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":10958},"source":{"system":"sec-edgar","filing":"0001670893-26-000002","document":"wk-form4_1778792215.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000167089326000002/wk-form4_1778792215.xml","form_type":"4"}},{"id":779468,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":47390,"kind":"person","name":"York Gwill","position":1,"cik":"0002008499","reported_name":"York Gwill","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-14T20:55:59.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":10958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and was not sold to the Reporting Person. As such, the Reporting person did not pay any consideration for the derivative securities."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":10958,"derivative":{"exercise_price":24.63,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":10958},"source":{"system":"sec-edgar","filing":"0002008499-26-000005","document":"wk-form4_1778792156.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008499/000200849926000005/wk-form4_1778792156.xml","form_type":"4"}},{"id":868514,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":46948,"kind":"person","name":"Etkin Amit","position":1,"cik":"0002007795","reported_name":"Etkin Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2026-03-04T00:16:05.000Z","date":"2026-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":6227,"price":19.69,"value":122609.63,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld for payment of taxes upon vesting of restricted stock units previously reported in Table I and does not represent an open market transaction by the reporting person."}],"balance_after":1233949,"source":{"system":"sec-edgar","filing":"0002007795-26-000002","document":"wk-form4_1772583360.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000200779526000002/wk-form4_1772583360.xml","form_type":"4"}},{"id":868575,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER  & CBO"}}],"security":"Common Stock","published_at":"2026-03-03T19:15:26.000Z","date":"2026-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2806,"price":19.69,"value":55250.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld for payment of taxes upon vesting of restricted stock units previously reported in Table I and does not represent an open market transaction by the reporting person."}],"balance_after":24060,"source":{"system":"sec-edgar","filing":"0002009130-26-000002","document":"wk-form4_1772583322.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000200913026000002/wk-form4_1772583322.xml","form_type":"4"}},{"id":905412,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":46948,"kind":"person","name":"Etkin Amit","position":1,"cik":"0002007795","reported_name":"Etkin Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-13T22:20:16.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":306000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":306000,"derivative":{"exercise_price":16.71,"expiration_date":"2036-02-10","underlying":"Common Stock","underlying_shares":306000},"source":{"system":"sec-edgar","filing":"0002007795-26-000001","document":"wk-form4_1771021213.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000200779526000001/wk-form4_1771021213.xml","form_type":"4"}},{"id":905411,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66520,"kind":"person","name":"Hanley Jr. Michael Conick","position":1,"cik":"0001791413","reported_name":"Hanley Jr. Michael Conick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-13T22:17:31.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":131000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":131000,"derivative":{"exercise_price":16.71,"expiration_date":"2036-02-10","underlying":"Common Stock","underlying_shares":131000},"source":{"system":"sec-edgar","filing":"0001791413-26-000001","document":"wk-form4_1771021048.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000179141326000001/wk-form4_1771021048.xml","form_type":"4"}},{"id":905414,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-13T17:19:32.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":124000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":124000,"derivative":{"exercise_price":16.71,"expiration_date":"2036-02-10","underlying":"Common Stock","underlying_shares":124000},"source":{"system":"sec-edgar","filing":"0002008707-26-000001","document":"wk-form4_1771021170.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000200870726000001/wk-form4_1771021170.xml","form_type":"4"}},{"id":905417,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER  & CBO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-02-13T17:18:38.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option shall vest on February 11, 2027, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":200000,"derivative":{"exercise_price":16.71,"expiration_date":"2036-02-10","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0002009130-26-000001","document":"wk-form4_1771021115.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000200913026000001/wk-form4_1771021115.xml","form_type":"4"}},{"id":947236,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":47390,"kind":"person","name":"York Gwill","position":1,"cik":"0002008499","reported_name":"York Gwill","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:47.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":5243,"price":11.82,"value":61972.26,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $62,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1,311 shares underlying the option shall vest on March 31, 2026, 1,311 shares underlying the option shall vest on June 30, 2026, 1,310 shares underlying the option shall vest on September 30, 2026 and 1,311 shares underlying the option shall vest on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":5243,"derivative":{"exercise_price":16.59,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":5243},"source":{"system":"sec-edgar","filing":"0002008499-26-000002","document":"wk-form4_1767736064.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008499/000200849926000002/wk-form4_1767736064.xml","form_type":"4"}},{"id":947231,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":45308,"kind":"person","name":"Cox Christopher Nixon","position":1,"cik":"0002008212","reported_name":"Cox Christopher Nixon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:14.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":7189,"price":11.82,"value":84973.98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $85,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1,797 shares underlying the option shall vest on March 31, 2026, 1,797 shares underlying the option shall vest on June 30, 2026, 1,798 shares underlying the option shall vest on September 30, 2026 and 1,797 shares underlying the option shall vest on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":7189,"derivative":{"exercise_price":16.59,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":7189},"source":{"system":"sec-edgar","filing":"0002008212-26-000002","document":"wk-form4_1767736023.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008212/000200821226000002/wk-form4_1767736023.xml","form_type":"4"}},{"id":947248,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":47392,"kind":"person","name":"Manji Husseini","position":1,"cik":"0002009654","reported_name":"Manji Husseini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-06T21:46:29.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":4228,"price":11.82,"value":49974.96,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1,057 shares underlying the option shall vest on each of March 31, 2026, June 30, 2026, September 30, 2026 and December 31, 2026,  subject to the Reporting Person's continuous service through each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $50,000."}],"balance_after":4228,"derivative":{"exercise_price":16.59,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":4228},"source":{"system":"sec-edgar","filing":"0002009654-26-000002","document":"wk-form4_1767735986.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009654/000200965426000002/wk-form4_1767735986.xml","form_type":"4"}},{"id":947209,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":39725,"kind":"person","name":"Sanchez Ramiro","position":1,"cik":"0001830326","reported_name":"Sanchez Ramiro","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:45:48.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":3806,"price":11.82,"value":44986.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $45,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"952 shares underlying the option shall vest on March 31, 2026, 951 shares underlying the option shall vest on June 30, 2026, 952 shares underlying the option shall vest on September 30, 2026 and 951 shares underlying the option shall vest on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":3806,"derivative":{"exercise_price":16.59,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":3806},"source":{"system":"sec-edgar","filing":"0001830326-26-000002","document":"wk-form4_1767735946.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000183032626000002/wk-form4_1767735946.xml","form_type":"4"}},{"id":1066688,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":39725,"kind":"person","name":"Sanchez Ramiro","position":1,"cik":"0001830326","reported_name":"Sanchez Ramiro","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-08-14T21:22:27.000Z","date":"2025-08-12","kind":"grant","planned":false,"acquired":true,"shares":3928,"price":2.21,"value":8680.88,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $8,682.07."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1,383 shares underlying the option shall vest on September 30, 2025, and 2,545 shares underlying the option shall vest on December 31, 2025, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":3928,"derivative":{"exercise_price":3.18,"expiration_date":"2035-08-11","underlying":"Common Stock","underlying_shares":3928},"source":{"system":"sec-edgar","filing":"0001999480-25-000081","document":"wk-form4_1755206542.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000081/wk-form4_1755206542.xml","form_type":"4"}},{"id":1066687,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":39725,"kind":"person","name":"Sanchez Ramiro","position":1,"cik":"0001830326","reported_name":"Sanchez Ramiro","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-08-14T21:22:27.000Z","date":"2025-08-12","kind":"grant","planned":false,"acquired":true,"shares":30574,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest in 36 equal monthly installments commencing on September 12, 2025, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":30574,"derivative":{"exercise_price":3.18,"expiration_date":"2035-08-11","underlying":"Common Stock","underlying_shares":30574},"source":{"system":"sec-edgar","filing":"0001999480-25-000081","document":"wk-form4_1755206542.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000081/wk-form4_1755206542.xml","form_type":"4"}},{"id":1090763,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66520,"kind":"person","name":"Hanley Jr. Michael Conick","position":1,"cik":"0001791413","reported_name":"Hanley Jr. Michael Conick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T21:22:49.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":4.2,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001999480-25-000065","document":"wk-form4_1752009762.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000065/wk-form4_1752009762.xml","form_type":"4"}},{"id":1090762,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66520,"kind":"person","name":"Hanley Jr. Michael Conick","position":1,"cik":"0001791413","reported_name":"Hanley Jr. Michael Conick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T21:22:49.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":125000,"derivative":{"exercise_price":2.35,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001999480-25-000065","document":"wk-form4_1752009762.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000065/wk-form4_1752009762.xml","form_type":"4"}},{"id":1090761,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66520,"kind":"person","name":"Hanley Jr. Michael Conick","position":1,"cik":"0001791413","reported_name":"Hanley Jr. Michael Conick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T21:22:49.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":188000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying the option vested on May 20, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":12.4,"expiration_date":"2034-05-19","underlying":"Common Stock","underlying_shares":188000},"source":{"system":"sec-edgar","filing":"0001999480-25-000065","document":"wk-form4_1752009762.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000065/wk-form4_1752009762.xml","form_type":"4"}},{"id":1090760,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66520,"kind":"person","name":"Hanley Jr. Michael Conick","position":1,"cik":"0001791413","reported_name":"Hanley Jr. Michael Conick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T21:22:49.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":188000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying the option vested on May 20, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":188000,"derivative":{"exercise_price":2.35,"expiration_date":"2034-05-19","underlying":"Common Stock","underlying_shares":188000},"source":{"system":"sec-edgar","filing":"0001999480-25-000065","document":"wk-form4_1752009762.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000065/wk-form4_1752009762.xml","form_type":"4"}},{"id":1090759,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66520,"kind":"person","name":"Hanley Jr. Michael Conick","position":1,"cik":"0001791413","reported_name":"Hanley Jr. Michael Conick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T21:22:49.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":14.88,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001999480-25-000065","document":"wk-form4_1752009762.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000065/wk-form4_1752009762.xml","form_type":"4"}},{"id":1090758,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66520,"kind":"person","name":"Hanley Jr. Michael Conick","position":1,"cik":"0001791413","reported_name":"Hanley Jr. Michael Conick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T21:22:49.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":8000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":8000,"derivative":{"exercise_price":2.35,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001999480-25-000065","document":"wk-form4_1752009762.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000065/wk-form4_1752009762.xml","form_type":"4"}},{"id":1090757,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":46948,"kind":"person","name":"Etkin Amit","position":1,"cik":"0002007795","reported_name":"Etkin Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T21:21:22.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":215000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":4.2,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0001999480-25-000063","document":"wk-form4_1752009676.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000063/wk-form4_1752009676.xml","form_type":"4"}},{"id":1090756,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":46948,"kind":"person","name":"Etkin Amit","position":1,"cik":"0002007795","reported_name":"Etkin Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T21:21:22.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":215000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":215000,"derivative":{"exercise_price":2.35,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0001999480-25-000063","document":"wk-form4_1752009676.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000063/wk-form4_1752009676.xml","form_type":"4"}},{"id":1090755,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":46948,"kind":"person","name":"Etkin Amit","position":1,"cik":"0002007795","reported_name":"Etkin Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T21:21:22.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":223000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":14.88,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":223000},"source":{"system":"sec-edgar","filing":"0001999480-25-000063","document":"wk-form4_1752009676.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000063/wk-form4_1752009676.xml","form_type":"4"}},{"id":1090754,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":46948,"kind":"person","name":"Etkin Amit","position":1,"cik":"0002007795","reported_name":"Etkin Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T21:21:22.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":223000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":223000,"derivative":{"exercise_price":2.35,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":223000},"source":{"system":"sec-edgar","filing":"0001999480-25-000063","document":"wk-form4_1752009676.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000063/wk-form4_1752009676.xml","form_type":"4"}},{"id":1090753,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":46948,"kind":"person","name":"Etkin Amit","position":1,"cik":"0002007795","reported_name":"Etkin Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T21:21:22.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":247290,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date"}],"balance_after":0,"derivative":{"exercise_price":5.3,"expiration_date":"2033-12-19","underlying":"Common Stock","underlying_shares":247290},"source":{"system":"sec-edgar","filing":"0001999480-25-000063","document":"wk-form4_1752009676.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000063/wk-form4_1752009676.xml","form_type":"4"}},{"id":1090752,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":46948,"kind":"person","name":"Etkin Amit","position":1,"cik":"0002007795","reported_name":"Etkin Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T21:21:22.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":247290,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date"}],"balance_after":247290,"derivative":{"exercise_price":2.35,"expiration_date":"2033-12-19","underlying":"Common Stock","underlying_shares":247290},"source":{"system":"sec-edgar","filing":"0001999480-25-000063","document":"wk-form4_1752009676.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000063/wk-form4_1752009676.xml","form_type":"4"}},{"id":1090751,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":46948,"kind":"person","name":"Etkin Amit","position":1,"cik":"0002007795","reported_name":"Etkin Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T21:21:22.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34620,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":6.23,"expiration_date":"2033-04-13","underlying":"Common Stock","underlying_shares":34620},"source":{"system":"sec-edgar","filing":"0001999480-25-000063","document":"wk-form4_1752009676.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000063/wk-form4_1752009676.xml","form_type":"4"}},{"id":1090750,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":46948,"kind":"person","name":"Etkin Amit","position":1,"cik":"0002007795","reported_name":"Etkin Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T21:21:22.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":34620,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":34620,"derivative":{"exercise_price":2.35,"expiration_date":"2033-04-13","underlying":"Common Stock","underlying_shares":34620},"source":{"system":"sec-edgar","filing":"0001999480-25-000063","document":"wk-form4_1752009676.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000063/wk-form4_1752009676.xml","form_type":"4"}},{"id":1090773,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":76000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":4.2,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":76000},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090772,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":76000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":76000,"derivative":{"exercise_price":2.35,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":76000},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090771,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":73000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":14.88,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":73000},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090770,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":73000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":73000,"derivative":{"exercise_price":2.35,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":73000},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090769,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":123645,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares underlying the option vested on December 20, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.3,"expiration_date":"2033-12-19","underlying":"Common Stock","underlying_shares":123645},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090768,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":123645,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares underlying the option vested on December 20, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":123645,"derivative":{"exercise_price":2.35,"expiration_date":"2033-12-19","underlying":"Common Stock","underlying_shares":123645},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090767,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":33008,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":6.23,"expiration_date":"2033-04-13","underlying":"Common Stock","underlying_shares":33008},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090766,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":33008,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":33008,"derivative":{"exercise_price":2.35,"expiration_date":"2033-04-13","underlying":"Common Stock","underlying_shares":33008},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090765,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22481,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":6.23,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":22481},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090764,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:22:02.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":22481,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":22481,"derivative":{"exercise_price":2.35,"expiration_date":"2032-08-01","underlying":"Common Stock","underlying_shares":22481},"source":{"system":"sec-edgar","filing":"0001999480-25-000064","document":"wk-form4_1752009714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000064/wk-form4_1752009714.xml","form_type":"4"}},{"id":1090786,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER  & CBO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:20:36.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":135000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":4.2,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001999480-25-000062","document":"wk-form4_1752009629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000199948025000062/wk-form4_1752009629.xml","form_type":"4"}},{"id":1090785,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER  & CBO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:20:36.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":135000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":135000,"derivative":{"exercise_price":2.35,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001999480-25-000062","document":"wk-form4_1752009629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000199948025000062/wk-form4_1752009629.xml","form_type":"4"}},{"id":1090784,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER  & CBO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:20:36.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":14.88,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001999480-25-000062","document":"wk-form4_1752009629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000199948025000062/wk-form4_1752009629.xml","form_type":"4"}},{"id":1090783,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER  & CBO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:20:36.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":90000,"derivative":{"exercise_price":2.35,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001999480-25-000062","document":"wk-form4_1752009629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000199948025000062/wk-form4_1752009629.xml","form_type":"4"}},{"id":1090782,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER  & CBO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:20:36.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":202329,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.3,"expiration_date":"2033-12-19","underlying":"Common Stock","underlying_shares":202329},"source":{"system":"sec-edgar","filing":"0001999480-25-000062","document":"wk-form4_1752009629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000199948025000062/wk-form4_1752009629.xml","form_type":"4"}},{"id":1090781,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER  & CBO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:20:36.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":202329,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-third (1/3rd) of the shares underlying the option vested upon the completion of the Issuer's initial public offering and two-thirds (2/3) of the shares underlying the option vested or shall vest over a period of four years. 25% of the shares underlying the time-based portion vested on December 20, 2024, and 1/48 of the shares underlying the time-based portion vested or shall vest on a monthly basis thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":202329,"derivative":{"exercise_price":2.35,"expiration_date":"2033-12-19","underlying":"Common Stock","underlying_shares":202329},"source":{"system":"sec-edgar","filing":"0001999480-25-000062","document":"wk-form4_1752009629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000199948025000062/wk-form4_1752009629.xml","form_type":"4"}},{"id":1090780,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER  & CBO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:20:36.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":33833,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":6.23,"expiration_date":"2033-04-13","underlying":"Common Stock","underlying_shares":33833},"source":{"system":"sec-edgar","filing":"0001999480-25-000062","document":"wk-form4_1752009629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000199948025000062/wk-form4_1752009629.xml","form_type":"4"}},{"id":1090779,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER  & CBO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:20:36.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":33833,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":33833,"derivative":{"exercise_price":2.35,"expiration_date":"2033-04-13","underlying":"Common Stock","underlying_shares":33833},"source":{"system":"sec-edgar","filing":"0001999480-25-000062","document":"wk-form4_1752009629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000199948025000062/wk-form4_1752009629.xml","form_type":"4"}},{"id":1090778,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER  & CBO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:20:36.000Z","date":"2025-07-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44962,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One forty-eighth (1/48th) of the shares underlying the option vested or shall vest on a monthly basis commencing on the one-month anniversary of September 21, 2022, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":6.23,"expiration_date":"2032-09-21","underlying":"Common Stock","underlying_shares":44962},"source":{"system":"sec-edgar","filing":"0001999480-25-000062","document":"wk-form4_1752009629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000199948025000062/wk-form4_1752009629.xml","form_type":"4"}},{"id":1090777,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER  & CBO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-08T17:20:36.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":44962,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on July 3, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One forty-eighth (1/48th) of the shares underlying the option vested or shall vest on a monthly basis commencing on the one-month anniversary of September 21, 2022, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":44962,"derivative":{"exercise_price":2.35,"expiration_date":"2032-09-21","underlying":"Common Stock","underlying_shares":44962},"source":{"system":"sec-edgar","filing":"0001999480-25-000062","document":"wk-form4_1752009629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000199948025000062/wk-form4_1752009629.xml","form_type":"4"}},{"id":1147726,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":47392,"kind":"person","name":"Manji Husseini","position":1,"cik":"0002009654","reported_name":"Manji Husseini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-15T20:16:52.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":15287,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15287,"derivative":{"exercise_price":2.37,"expiration_date":"2035-05-12","underlying":"Common Stock","underlying_shares":15287},"source":{"system":"sec-edgar","filing":"0001999480-25-000041","document":"wk-form4_1747340204.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009654/000199948025000041/wk-form4_1747340204.xml","form_type":"4"}},{"id":1147715,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":45308,"kind":"person","name":"Cox Christopher Nixon","position":1,"cik":"0002008212","reported_name":"Cox Christopher Nixon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-15T20:16:40.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":15287,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15287,"derivative":{"exercise_price":2.37,"expiration_date":"2035-05-12","underlying":"Common Stock","underlying_shares":15287},"source":{"system":"sec-edgar","filing":"0001999480-25-000040","document":"wk-form4_1747340192.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008212/000199948025000040/wk-form4_1747340192.xml","form_type":"4"}},{"id":1147712,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":47389,"kind":"person","name":"Dreyfus Andrew","position":1,"cik":"0001670893","reported_name":"Dreyfus Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-15T20:16:28.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":15287,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15287,"derivative":{"exercise_price":2.37,"expiration_date":"2035-05-12","underlying":"Common Stock","underlying_shares":15287},"source":{"system":"sec-edgar","filing":"0001999480-25-000039","document":"wk-form4_1747340182.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000039/wk-form4_1747340182.xml","form_type":"4"}},{"id":1147716,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":47390,"kind":"person","name":"York Gwill","position":1,"cik":"0002008499","reported_name":"York Gwill","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-15T20:16:18.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":15287,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The derivative securities were granted to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest on the earlier of the one-year anniversary of the date of grant and the date of Issuer's next Annual Meeting following the date of grant, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15287,"derivative":{"exercise_price":2.37,"expiration_date":"2035-05-12","underlying":"Common Stock","underlying_shares":15287},"source":{"system":"sec-edgar","filing":"0001999480-25-000038","document":"wk-form4_1747340169.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008499/000199948025000038/wk-form4_1747340169.xml","form_type":"4"}},{"id":1278929,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66520,"kind":"person","name":"Hanley Jr. Michael Conick","position":1,"cik":"0001791413","reported_name":"Hanley Jr. Michael Conick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-02-07T21:22:53.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":125000,"derivative":{"exercise_price":4.2,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001999480-25-000016","document":"wk-form4_1738963366.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000016/wk-form4_1738963366.xml","form_type":"4"}},{"id":1278928,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":46948,"kind":"person","name":"Etkin Amit","position":1,"cik":"0002007795","reported_name":"Etkin Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-02-07T21:21:28.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":215000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":215000,"derivative":{"exercise_price":4.2,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0001999480-25-000013","document":"wk-form4_1738963279.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000013/wk-form4_1738963279.xml","form_type":"4"}},{"id":1278952,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER  & CBO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-02-07T16:22:23.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":135000,"derivative":{"exercise_price":4.2,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001999480-25-000015","document":"wk-form4_1738963337.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000199948025000015/wk-form4_1738963337.xml","form_type":"4"}},{"id":1278951,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-02-07T16:21:55.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":76000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":76000,"derivative":{"exercise_price":4.2,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":76000},"source":{"system":"sec-edgar","filing":"0001999480-25-000014","document":"wk-form4_1738963307.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000199948025000014/wk-form4_1738963307.xml","form_type":"4"}},{"id":1311225,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":47390,"kind":"person","name":"York Gwill","position":1,"cik":"0002008499","reported_name":"York Gwill","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-06T21:18:22.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":19558,"price":3.17,"value":61998.86,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $62,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"4,889 shares underlying the option shall vest on March 31, 2025, 4,890 shares underlying the option shall vest on June 30, 2025, 4,889 shares underlying the option shall vest on September 30, 2025 and 4,890 shares underlying the option shall vest on December 31, 2025, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":19558,"derivative":{"exercise_price":4.38,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":19558},"source":{"system":"sec-edgar","filing":"0001999480-25-000006","document":"wk-form4_1736198292.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008499/000199948025000006/wk-form4_1736198292.xml","form_type":"4"}},{"id":1311227,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":47392,"kind":"person","name":"Manji Husseini","position":1,"cik":"0002009654","reported_name":"Manji Husseini","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-06T21:17:45.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":14195,"price":3.17,"value":44998.15,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $45,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"3,548 shares underlying the option shall vest on March 31, 2025, and 3,549 shares underlying the option shall vest on each of June 30, 2025, September 30, 2025 and December 31, 2025, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":14195,"derivative":{"exercise_price":4.38,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":14195},"source":{"system":"sec-edgar","filing":"0001999480-25-000005","document":"wk-form4_1736198252.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009654/000199948025000005/wk-form4_1736198252.xml","form_type":"4"}},{"id":1311224,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":45308,"kind":"person","name":"Cox Christopher Nixon","position":1,"cik":"0002008212","reported_name":"Cox Christopher Nixon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-06T21:17:04.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":25236,"price":3.17,"value":79998.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $80,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"6,309 shares underlying the option shall vest on each of March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":25236,"derivative":{"exercise_price":4.38,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":25236},"source":{"system":"sec-edgar","filing":"0001999480-25-000004","document":"wk-form4_1736198217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008212/000199948025000004/wk-form4_1736198217.xml","form_type":"4"}},{"id":1456364,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-11T16:15:04.000Z","date":"2024-07-10","kind":"purchase","planned":false,"acquired":true,"shares":2931,"price":13.22,"value":38747.82,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.04 to $13.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (the \"Friedman Trust\"). The spouse of the Reporting Person is the beneficiary of the Friedman Trust, and the Reporting Person may be deemed to share beneficial ownership of the securities held by the Friedman Trust."}],"balance_after":39851,"source":{"system":"sec-edgar","filing":"0001415889-24-019488","document":"form4-07112024_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000141588924019488/form4-07112024_040701.xml","form_type":"4"}},{"id":1456363,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-11T16:15:04.000Z","date":"2024-07-09","kind":"purchase","planned":false,"acquired":true,"shares":1388,"price":13.15,"value":18252.2,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (the \"Friedman Trust\"). The spouse of the Reporting Person is the beneficiary of the Friedman Trust, and the Reporting Person may be deemed to share beneficial ownership of the securities held by the Friedman Trust."}],"balance_after":36920,"source":{"system":"sec-edgar","filing":"0001415889-24-019488","document":"form4-07112024_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000141588924019488/form4-07112024_040701.xml","form_type":"4"}},{"id":1456362,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-11T16:15:04.000Z","date":"2024-07-09","kind":"purchase","planned":false,"acquired":true,"shares":10681,"price":12.53,"value":133832.93,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.05 to $13.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by Robert L. Friedman 2003 Long-Term Trust fbo Lisa Savitz (the \"Friedman Trust\"). The spouse of the Reporting Person is the beneficiary of the Friedman Trust, and the Reporting Person may be deemed to share beneficial ownership of the securities held by the Friedman Trust."}],"balance_after":35532,"source":{"system":"sec-edgar","filing":"0001415889-24-019488","document":"form4-07112024_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000141588924019488/form4-07112024_040701.xml","form_type":"4"}},{"id":1505785,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66520,"kind":"person","name":"Hanley Jr. Michael Conick","position":1,"cik":"0001791413","reported_name":"Hanley Jr. Michael Conick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-05-22T21:19:12.000Z","date":"2024-05-20","kind":"grant","planned":false,"acquired":true,"shares":188000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option shall vest on May 20, 2025, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":188000,"derivative":{"exercise_price":12.4,"expiration_date":"2034-05-19","underlying":"Common Stock","underlying_shares":188000},"source":{"system":"sec-edgar","filing":"0001415889-24-014118","document":"form4-05222024_090504.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000141588924014118/form4-05222024_090504.xml","form_type":"4"}},{"id":1556611,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-04-01T16:15:30.000Z","date":"2024-03-28","kind":"purchase","planned":false,"acquired":true,"shares":4550,"price":16.56,"value":75348.0,"ownership":{"direct":true},"balance_after":26866,"source":{"system":"sec-edgar","filing":"0001415889-24-009533","document":"form4-04012024_040402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000141588924009533/form4-04012024_040402.xml","form_type":"4"}},{"id":1556610,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-04-01T16:15:30.000Z","date":"2024-03-28","kind":"purchase","planned":false,"acquired":true,"shares":1600,"price":15.8,"value":25280.0,"ownership":{"direct":true},"balance_after":22316,"source":{"system":"sec-edgar","filing":"0001415889-24-009533","document":"form4-04012024_040402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000141588924009533/form4-04012024_040402.xml","form_type":"4"}},{"id":1581836,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":35728,"kind":"person","name":"Radhakrishnan Maha","position":1,"cik":"0002013423","reported_name":"Radhakrishnan Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-12T20:49:43.000Z","date":"2024-03-08","kind":"grant","planned":false,"acquired":true,"shares":1590,"price":10.213,"value":16238.67,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $16,263.74."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"123 shares underlying the option shall vest on March 31, 2024, and 489 shares underlying the option shall vest on each of June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":1590,"derivative":{"exercise_price":13.76,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":1590},"source":{"system":"sec-edgar","filing":"0001415889-24-007643","document":"form4-03122024_080330.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2013423/000141588924007643/form4-03122024_080330.xml","form_type":"4"}},{"id":1581835,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":35728,"kind":"person","name":"Radhakrishnan Maha","position":1,"cik":"0002013423","reported_name":"Radhakrishnan Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-12T20:49:43.000Z","date":"2024-03-08","kind":"grant","planned":false,"acquired":true,"shares":30574,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest in 36 equal monthly installments commencing on April 8, 2024, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":30574,"derivative":{"exercise_price":13.76,"expiration_date":"2034-03-07","underlying":"Common Stock","underlying_shares":30574},"source":{"system":"sec-edgar","filing":"0001415889-24-007643","document":"form4-03122024_080330.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2013423/000141588924007643/form4-03122024_080330.xml","form_type":"4"}},{"id":1592189,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":10106,"kind":"person","name":"Apeiron Investment Group Ltd.","position":1,"cik":"0001845711","reported_name":"Apeiron Investment Group Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":86953,"kind":"organization","name":"Apeiron Presight Capital Fund II, L.P.","position":2,"cik":"0001840676","reported_name":"Apeiron Presight Capital Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":10108,"kind":"person","name":"Angermayer Christian","position":3,"cik":"0001845872","reported_name":"Angermayer Christian","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Series B Preferred Stock","published_at":"2024-03-06T14:15:59.000Z","date":"2024-02-06","kind":"exercise","planned":false,"acquired":false,"shares":416665,"ownership":{"direct":false,"nature":"By Apeiron Presight Capital Fund II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"In connection with the closing of the Issuer's initial public offering, each share of Series B Preferred automatically converted into common stock on a 2.1226069 for 1 basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are held by Apeiron Presight Capital Fund II, L.P. (\"Apeiron Presight\"). Apeiron Investment Group Ltd. (\"Apeiron\") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. (\"Presight Management\"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":196299},"source":{"system":"sec-edgar","filing":"0000950170-24-026885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000095017024026885/ownership.xml","form_type":"4"}},{"id":1592188,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":10106,"kind":"person","name":"Apeiron Investment Group Ltd.","position":1,"cik":"0001845711","reported_name":"Apeiron Investment Group Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":86953,"kind":"organization","name":"Apeiron Presight Capital Fund II, L.P.","position":2,"cik":"0001840676","reported_name":"Apeiron Presight Capital Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":10108,"kind":"person","name":"Angermayer Christian","position":3,"cik":"0001845872","reported_name":"Angermayer Christian","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Series A Preferred Stock","published_at":"2024-03-06T14:15:59.000Z","date":"2024-02-06","kind":"exercise","planned":false,"acquired":false,"shares":1063918,"ownership":{"direct":false,"nature":"By Apeiron Presight Capital Fund II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are held by Apeiron Presight Capital Fund II, L.P. (\"Apeiron Presight\"). Apeiron Investment Group Ltd. (\"Apeiron\") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. (\"Presight Management\"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":478359},"source":{"system":"sec-edgar","filing":"0000950170-24-026885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000095017024026885/ownership.xml","form_type":"4"}},{"id":1592187,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":10106,"kind":"person","name":"Apeiron Investment Group Ltd.","position":1,"cik":"0001845711","reported_name":"Apeiron Investment Group Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":86953,"kind":"organization","name":"Apeiron Presight Capital Fund II, L.P.","position":2,"cik":"0001840676","reported_name":"Apeiron Presight Capital Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":10108,"kind":"person","name":"Angermayer Christian","position":3,"cik":"0001845872","reported_name":"Angermayer Christian","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Series A Preferred Stock","published_at":"2024-03-06T14:15:59.000Z","date":"2024-02-06","kind":"exercise","planned":false,"acquired":false,"shares":406072,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held by Apeiron Investment Group Ltd. (\"Apeiron\"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":182577},"source":{"system":"sec-edgar","filing":"0000950170-24-026885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000095017024026885/ownership.xml","form_type":"4"}},{"id":1592186,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":10106,"kind":"person","name":"Apeiron Investment Group Ltd.","position":1,"cik":"0001845711","reported_name":"Apeiron Investment Group Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":86953,"kind":"organization","name":"Apeiron Presight Capital Fund II, L.P.","position":2,"cik":"0001840676","reported_name":"Apeiron Presight Capital Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":10108,"kind":"person","name":"Angermayer Christian","position":3,"cik":"0001845872","reported_name":"Angermayer Christian","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Warrants to Purchase Series A Preferred Stock","published_at":"2024-03-06T14:15:59.000Z","date":"2024-02-06","kind":"exercise","planned":false,"acquired":false,"shares":444561,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"In connection with the closing of the Issuer's initial public offering, the Warrants were exercised on a cashless basis into shares of Series A Preferred Stock, which were automatically converted into shares of Common Stock on a 2.2241 for 1 basis."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held by Apeiron Investment Group Ltd. (\"Apeiron\"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":69304},"source":{"system":"sec-edgar","filing":"0000950170-24-026885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000095017024026885/ownership.xml","form_type":"4"}},{"id":1592185,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":10106,"kind":"person","name":"Apeiron Investment Group Ltd.","position":1,"cik":"0001845711","reported_name":"Apeiron Investment Group Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":86953,"kind":"organization","name":"Apeiron Presight Capital Fund II, L.P.","position":2,"cik":"0001840676","reported_name":"Apeiron Presight Capital Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":10108,"kind":"person","name":"Angermayer Christian","position":3,"cik":"0001845872","reported_name":"Angermayer Christian","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2024-03-06T14:15:59.000Z","date":"2024-02-06","kind":"exercise","planned":false,"acquired":true,"shares":674658,"ownership":{"direct":false,"nature":"By Apeiron Presight Capital Fund II, L.P.("},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reportable securities are held by Apeiron Presight Capital Fund II, L.P. (\"Apeiron Presight\"). Apeiron Investment Group Ltd. (\"Apeiron\") and Fabian Hansen are the managing members of Presight Capital Management I, L.L.C. (\"Presight Management\"), which is the general partner of Apeiron Presight. As a result, each of Apeiron, Mr. Hansen and Presight Management may be deemed to share beneficial ownership of the securities."}],"balance_after":674658,"source":{"system":"sec-edgar","filing":"0000950170-24-026885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000095017024026885/ownership.xml","form_type":"4"}},{"id":1592184,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":10106,"kind":"person","name":"Apeiron Investment Group Ltd.","position":1,"cik":"0001845711","reported_name":"Apeiron Investment Group Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":86953,"kind":"organization","name":"Apeiron Presight Capital Fund II, L.P.","position":2,"cik":"0001840676","reported_name":"Apeiron Presight Capital Fund II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":10108,"kind":"person","name":"Angermayer Christian","position":3,"cik":"0001845872","reported_name":"Angermayer Christian","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2024-03-06T14:15:59.000Z","date":"2024-02-06","kind":"exercise","planned":false,"acquired":true,"shares":251881,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of Series A preferred stock automatically converted into common stock 2.2241 for 1 basis."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reportable securities are held by Apeiron Investment Group Ltd. (\"Apeiron\"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities."}],"balance_after":251881,"source":{"system":"sec-edgar","filing":"0000950170-24-026885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000095017024026885/ownership.xml","form_type":"4"}},{"id":1597761,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":46948,"kind":"person","name":"Etkin Amit","position":1,"cik":"0002007795","reported_name":"Etkin Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-03-05T23:00:27.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":223000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option shall vest on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":223000,"derivative":{"exercise_price":14.88,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":223000},"source":{"system":"sec-edgar","filing":"0001415889-24-006822","document":"form4-03052024_060301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000141588924006822/form4-03052024_060301.xml","form_type":"4"}},{"id":1597760,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":46948,"kind":"person","name":"Etkin Amit","position":1,"cik":"0002007795","reported_name":"Etkin Amit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-03-05T23:00:27.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":34711,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs shall vest in two equal installments on September 1, 2025 and March 1, 2026, subject to the Reporting Person's continuous service through each such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock."}],"balance_after":1240176,"source":{"system":"sec-edgar","filing":"0001415889-24-006822","document":"form4-03052024_060301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1999480/000141588924006822/form4-03052024_060301.xml","form_type":"4"}},{"id":1597829,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":66521,"kind":"person","name":"Savitz Adam","position":1,"cik":"0002008707","reported_name":"Savitz Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-03-05T18:00:40.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":73000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option shall vest on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":73000,"derivative":{"exercise_price":14.88,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":73000},"source":{"system":"sec-edgar","filing":"0001415889-24-006824","document":"form4-03052024_060306.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008707/000141588924006824/form4-03052024_060306.xml","form_type":"4"}},{"id":1597831,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-03-05T18:00:27.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option shall vest on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":90000,"derivative":{"exercise_price":14.88,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001415889-24-006823","document":"form4-03052024_060303.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000141588924006823/form4-03052024_060303.xml","form_type":"4"}},{"id":1597830,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":63408,"kind":"person","name":"Smith Nicholas Conrad","position":1,"cik":"0002009130","reported_name":"Smith Nicholas Conrad","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-05T18:00:27.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":19153,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs shall vest in two equal installments on September 1, 2025 and March 1, 2026, subject to the Reporting Person's continuous service through each such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock."}],"balance_after":20716,"source":{"system":"sec-edgar","filing":"0001415889-24-006823","document":"form4-03052024_060303.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009130/000141588924006823/form4-03052024_060303.xml","form_type":"4"}},{"id":1653812,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":26293,"kind":"organization","name":"Alpha Wave Global, LP","position":1,"cik":"0001558858","reported_name":"Alpha Wave Global, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26292,"kind":"organization","name":"Alpha Wave Ventures GP, Ltd","position":2,"cik":"0002007422","reported_name":"Alpha Wave Ventures GP, Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26294,"kind":"organization","name":"Lunate Holding RSC Ltd","position":3,"cik":"0002009522","reported_name":"Lunate Holding RSC Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26295,"kind":"organization","name":"Chimera Investment LLC","position":4,"cik":"0002009884","reported_name":"Chimera Investment LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock (Series C Preferred)","published_at":"2024-02-08T21:32:33.000Z","date":"2024-02-06","kind":"exercise","planned":false,"acquired":false,"shares":1144763,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of common stock on a 2.2241 for 1 basis into the number of shares of common stock shown in column 3 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of common stock on a 2.2241 for 1 basis into the number of shares of common stock shown in column 3 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of common stock on a 2.2241 for 1 basis into the number of shares of common stock shown in column 3 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities held by Alpha Wave Ventures II, LP (\"Alpha Wave Ventures\"). Alpha Wave Ventures GP, Ltd (\"Alpha Wave Ventures GP\") is the general partner of Alpha Wave Ventures. Alpha Wave Ventures GP is a joint venture between Alpha Wave Global, LP (\"Alpha Wave\") and Lunate Holding RSC LTD (\"Lunate\"). Lunate is a subsidiary of Chimera Investment LLC (\"Chimera,\" together with Alpha Wave Ventures GP, Alpha Wave and Lunate, the \"Reporting Persons\"). Richard Gerson is the Chairman and Chief Investment Officer of Alpha Wave. Chimera is controlled by its board of directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1144763},"source":{"system":"sec-edgar","filing":"0000902664-24-001290","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2009884/000090266424001290/ownership.xml","form_type":"4"}},{"id":1653811,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":26293,"kind":"organization","name":"Alpha Wave Global, LP","position":1,"cik":"0001558858","reported_name":"Alpha Wave Global, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26292,"kind":"organization","name":"Alpha Wave Ventures GP, Ltd","position":2,"cik":"0002007422","reported_name":"Alpha Wave Ventures GP, Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26294,"kind":"organization","name":"Lunate Holding RSC Ltd","position":3,"cik":"0002009522","reported_name":"Lunate Holding RSC Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26295,"kind":"organization","name":"Chimera Investment LLC","position":4,"cik":"0002009884","reported_name":"Chimera Investment LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock (Series B Preferred)","published_at":"2024-02-08T21:32:33.000Z","date":"2024-02-06","kind":"exercise","planned":false,"acquired":false,"shares":1962995,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of common stock on a 2.1226069 for 1 basis into the number of shares of common stock shown in column 3 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of common stock on a 2.1226069 for 1 basis into the number of shares of common stock shown in column 3 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of common stock on a 2.1226069 for 1 basis into the number of shares of common stock shown in column 3 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities held by Alpha Wave Ventures II, LP (\"Alpha Wave Ventures\"). Alpha Wave Ventures GP, Ltd (\"Alpha Wave Ventures GP\") is the general partner of Alpha Wave Ventures. Alpha Wave Ventures GP is a joint venture between Alpha Wave Global, LP (\"Alpha Wave\") and Lunate Holding RSC LTD (\"Lunate\"). Lunate is a subsidiary of Chimera Investment LLC (\"Chimera,\" together with Alpha Wave Ventures GP, Alpha Wave and Lunate, the \"Reporting Persons\"). Richard Gerson is the Chairman and Chief Investment Officer of Alpha Wave. Chimera is controlled by its board of directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1962995},"source":{"system":"sec-edgar","filing":"0000902664-24-001290","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2009884/000090266424001290/ownership.xml","form_type":"4"}},{"id":1653810,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":26293,"kind":"organization","name":"Alpha Wave Global, LP","position":1,"cik":"0001558858","reported_name":"Alpha Wave Global, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26292,"kind":"organization","name":"Alpha Wave Ventures GP, Ltd","position":2,"cik":"0002007422","reported_name":"Alpha Wave Ventures GP, Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26294,"kind":"organization","name":"Lunate Holding RSC Ltd","position":3,"cik":"0002009522","reported_name":"Lunate Holding RSC Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26295,"kind":"organization","name":"Chimera Investment LLC","position":4,"cik":"0002009884","reported_name":"Chimera Investment LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-08T21:32:33.000Z","date":"2024-02-06","kind":"purchase","planned":false,"acquired":true,"shares":600000,"price":16,"value":9600000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities held by Alpha Wave Ventures II, LP (\"Alpha Wave Ventures\"). Alpha Wave Ventures GP, Ltd (\"Alpha Wave Ventures GP\") is the general partner of Alpha Wave Ventures. Alpha Wave Ventures GP is a joint venture between Alpha Wave Global, LP (\"Alpha Wave\") and Lunate Holding RSC LTD (\"Lunate\"). Lunate is a subsidiary of Chimera Investment LLC (\"Chimera,\" together with Alpha Wave Ventures GP, Alpha Wave and Lunate, the \"Reporting Persons\"). Richard Gerson is the Chairman and Chief Investment Officer of Alpha Wave. Chimera is controlled by its board of directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":3707757,"source":{"system":"sec-edgar","filing":"0000902664-24-001290","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2009884/000090266424001290/ownership.xml","form_type":"4"}},{"id":1653809,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":26293,"kind":"organization","name":"Alpha Wave Global, LP","position":1,"cik":"0001558858","reported_name":"Alpha Wave Global, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26292,"kind":"organization","name":"Alpha Wave Ventures GP, Ltd","position":2,"cik":"0002007422","reported_name":"Alpha Wave Ventures GP, Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26294,"kind":"organization","name":"Lunate Holding RSC Ltd","position":3,"cik":"0002009522","reported_name":"Lunate Holding RSC Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26295,"kind":"organization","name":"Chimera Investment LLC","position":4,"cik":"0002009884","reported_name":"Chimera Investment LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-08T21:32:33.000Z","date":"2024-02-06","kind":"exercise","planned":false,"acquired":true,"shares":1144762,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of common stock on a 2.2241 for 1 basis into the number of shares of common stock shown in column 3 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities held by Alpha Wave Ventures II, LP (\"Alpha Wave Ventures\"). Alpha Wave Ventures GP, Ltd (\"Alpha Wave Ventures GP\") is the general partner of Alpha Wave Ventures. Alpha Wave Ventures GP is a joint venture between Alpha Wave Global, LP (\"Alpha Wave\") and Lunate Holding RSC LTD (\"Lunate\"). Lunate is a subsidiary of Chimera Investment LLC (\"Chimera,\" together with Alpha Wave Ventures GP, Alpha Wave and Lunate, the \"Reporting Persons\"). Richard Gerson is the Chairman and Chief Investment Officer of Alpha Wave. Chimera is controlled by its board of directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":3107757,"source":{"system":"sec-edgar","filing":"0000902664-24-001290","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2009884/000090266424001290/ownership.xml","form_type":"4"}},{"id":1653808,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":26293,"kind":"organization","name":"Alpha Wave Global, LP","position":1,"cik":"0001558858","reported_name":"Alpha Wave Global, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26292,"kind":"organization","name":"Alpha Wave Ventures GP, Ltd","position":2,"cik":"0002007422","reported_name":"Alpha Wave Ventures GP, Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26294,"kind":"organization","name":"Lunate Holding RSC Ltd","position":3,"cik":"0002009522","reported_name":"Lunate Holding RSC Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26295,"kind":"organization","name":"Chimera Investment LLC","position":4,"cik":"0002009884","reported_name":"Chimera Investment LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-08T21:32:33.000Z","date":"2024-02-06","kind":"exercise","planned":false,"acquired":true,"shares":1962995,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of common stock on a 2.1226069 for 1 basis into the number of shares of common stock shown in column 3 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities held by Alpha Wave Ventures II, LP (\"Alpha Wave Ventures\"). Alpha Wave Ventures GP, Ltd (\"Alpha Wave Ventures GP\") is the general partner of Alpha Wave Ventures. Alpha Wave Ventures GP is a joint venture between Alpha Wave Global, LP (\"Alpha Wave\") and Lunate Holding RSC LTD (\"Lunate\"). Lunate is a subsidiary of Chimera Investment LLC (\"Chimera,\" together with Alpha Wave Ventures GP, Alpha Wave and Lunate, the \"Reporting Persons\"). Richard Gerson is the Chairman and Chief Investment Officer of Alpha Wave. Chimera is controlled by its board of directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"For purposes of Section 16 of the Securities Exchange Act of 1934, each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1962995,"source":{"system":"sec-edgar","filing":"0000902664-24-001290","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2009884/000090266424001290/ownership.xml","form_type":"4"}},{"id":1655521,"issuer":{"id":4755,"kind":"organization","name":"Alto Neuroscience, Inc.","symbol":"ANRO"},"owners":[{"id":47390,"kind":"person","name":"York Gwill","position":1,"cik":"0002008499","reported_name":"York Gwill","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-02-07T21:41:23.000Z","date":"2024-02-06","kind":"exercise","planned":false,"acquired":false,"shares":53196,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":23917},"source":{"system":"sec-edgar","filing":"0001415889-24-002942","document":"form4-02072024_090216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2008499/000141588924002942/form4-02072024_090216.xml","form_type":"4"}}],"next_cursor":"2024-02-07T21:41:23.000000Z,1655521"}